Roger L Papke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4535037/publications.pdf

Version: 2024-02-01

135 papers	5,770 citations	57758 44 h-index	95266 68 g-index
140 all docs	140 docs citations	140 times ranked	3394 citing authors

#	Article	IF	Citations
1	An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the Î±7 subtype. Neuroscience Letters, 1996, 213, 201-204.	2.1	264
2	Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations. Biochemical Pharmacology, 2011, 82, 915-930.	4.4	236
3	Comparative pharmacology of rat and human Î±7 nAChR conducted with net charge analysis. British Journal of Pharmacology, 2002, 137, 49-61.	5.4	226
4	Single-channel currents of rat neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. Neuron, 1989, 3, 589-596.	8.1	182
5	3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat Î±7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Research, 1997, 768, 49-56.	2.2	162
6	Merging old and new perspectives on nicotinic acetylcholine receptors. Biochemical Pharmacology, 2014, 89, 1-11.	4.4	154
7	A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neuroscience Letters, 1994, 168, 130-134.	2.1	145
8	The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. Progress in Neurobiology, 1993, 41, 509-531.	5.7	118
9	Î±7 Receptor-selective agonists and modes of Î±7 receptor activation. European Journal of Pharmacology, 2000, 393, 179-195.	3.5	107
10	Hydroxy Metabolites of the Alzheimer's Drug Candidate 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (GTS-21): Their Molecular Properties, Interactions with Brain Nicotinic Receptors, and Brain Penetration. Molecular Pharmacology, 2004, 65, 56-67.	2.3	106
11	Investigation of the Molecular Mechanism of the Î±7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator PNU-120596 Provides Evidence for Two Distinct Desensitized States. Molecular Pharmacology, 2011, 80, 1013-1032.	2.3	99
12	Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity. PLoS ONE, 2015, 10, e0140907.	2.5	96
13	Characterization of the neuroprotective and toxic effects of Î±7 nicotinic receptor activation in PC12 cells. Brain Research, 1999, 830, 218-225.	2.2	94
14	Activation and Desensitization of Nicotinic Î±7-type Acetylcholine Receptors by Benzylidene Anabaseines and Nicotine. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 791-807.	2.5	83
15	Regulation of Neuronal Function by Choline and 4OH-GTS-21 Through Î±7 Nicotinic Receptors. Journal of Neurophysiology, 2003, 89, 1797-1806.	1.8	82
16	Extending the analysis of nicotinic receptor antagonists with the study of Î±6 nicotinic receptor subunit chimeras. Neuropharmacology, 2008, 54, 1189-1200.	4.1	82
17	Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. Brain Research, 2002, 948, 33-46.	2.2	79
18	The correction of alpha7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes. Neuroscience Letters, 1998, 256, 163-166.	2.1	78

#	Article	IF	Citations
19	The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. Neuropharmacology, 2015, 91, 34-42.	4.1	77
20	Looking below the surface of nicotinic acetylcholine receptors. Trends in Pharmacological Sciences, 2015, 36, 514-523.	8.7	76
21	New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on Î±7 nAChRs. Current Neuropharmacology, 2018, 16, 415-425.	2.9	76
22	Nicotinic Receptors on Local Circuit Neurons in Dentate Gyrus: A Potential Role in Regulation of Granule Cell Excitability. Journal of Neurophysiology, 2003, 89, 3018-3028.	1.8	72
23	Cytisine-Based Nicotinic Partial Agonists as Novel Antidepressant Compounds. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 377-386.	2.5	71
24	Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling. Neuropharmacology, 2020, 168, 108021.	4.1	71
25	The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. Journal of Neurochemistry, 2007, 101, 160-167.	3.9	66
26	Working with OpusXpress: Methods for high volume oocyte experiments. Methods, 2010, 51, 121-133.	3.8	64
27	The Î±7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. British Journal of Pharmacology, 2016, 173, 2506-2520.	5.4	64
28	The Activation and Inhibition of Human Nicotinic Acetylcholine Receptor by RJR-2403 Indicate a Selectivity for the Î±4Î²2 Receptor Subtype. Journal of Neurochemistry, 2001, 75, 204-216.	3.9	59
29	Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 501-518.	2.5	59
30	Electrophysiological Perspectives on the Therapeutic Use of Nicotinic Acetylcholine Receptor Partial Agonists. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 367-379.	2.5	59
31	Expeditious Synthesis, Enantiomeric Resolution, and Enantiomer Functional Characterization of		

#	Article	IF	Citations
37	Multiple calcium channels and kinases mediate Î±7 nicotinic receptor neuroprotection in PC12 cells. Journal of Neurochemistry, 2005, 94, 926-933.	3.9	53
38	Multiple Pharmacophores for the Selective Activation of Nicotinic Î±7-Type Acetylcholine Receptors. Molecular Pharmacology, 2008, 74, 1496-1511.	2.3	52
39	Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes. European Journal of Neuroscience, 2010, 31, 978-993.	2.6	52
40	The nicotinic acetylcholine receptors of zebrafish and an evaluation of pharmacological tools used for their study. Biochemical Pharmacology, 2012, 84, 352-365.	4.4	50
41	The Î±7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Experimental Neurology, 2015, 263, 277-284.	4.1	50
42	Molecular dissection of tropisetron, an Î±7 nicotinic acetylcholine receptor-selective partial agonist. Neuroscience Letters, 2005, 378, 140-144.	2.1	49
43	Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. British Journal of Pharmacology, 1997, 120, 429-438.	5.4	48
44	Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain. British Journal of Pharmacology, 1999, 127, 1337-1348.	5.4	47
45	The effective opening of nicotinic acetylcholine receptors with single agonist binding sites. Journal of General Physiology, 2011, 137, 369-384.	1.9	44
46	Critical Molecular Determinants of Î±7 Nicotinic Acetylcholine Receptor Allosteric Activation. Journal of Biological Chemistry, 2016, 291, 5049-5067.	3.4	43
47	Therapeutic Targeting of Î±7 Nicotinic Acetylcholine Receptors. Pharmacological Reviews, 2021, 73, 1118-1149.	16.0	43
48	Synthesis and evaluation of a conditionally-silent agonist for the Î±7 nicotinic acetylcholine receptor. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4145-4149.	2.2	41
49	The Minimal Pharmacophore for Silent Agonism of the Î±7 Nicotinic Acetylcholine Receptor. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 665-680.	2.5	41
50	Two Novel Î±7 Nicotinic Acetylcholine Receptor Ligands: In Vitro Properties and Their Efficacy in Collagen-Induced Arthritis in Mice. PLoS ONE, 2015, 10, e0116227.	2.5	38
51	Anti-inflammatory Silent Agonists. ACS Medicinal Chemistry Letters, 2017, 8, 989-991.	2.8	38
52	Rabies virus modifies host behaviour through a snake-toxin like region of its glycoprotein that inhibits neurotransmitter receptors in the CNS. Scientific Reports, 2017, 7, 12818.	3.3	38
53	Estimation of both the potency and efficacy of Î±7 nAChR agonists from single-concentration responses. Life Sciences, 2006, 78, 2812-2819.	4.3	37
54	Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology, 2007, 53, 134-144.	4.1	36

#	Article	IF	Citations
55	The Activity of GAT107, an Allosteric Activator and Positive Modulator of Î±7 Nicotinic Acetylcholine Receptors (nAChR), Is Regulated by Aromatic Amino Acids That Span the Subunit Interface. Journal of Biological Chemistry, 2014, 289, 4515-4531.	3.4	36
56	Diverse strategies targeting Î±7 homomeric and Î±6Î²2* heteromeric nicotinic acetylcholine receptors for smoking cessation. Annals of the New York Academy of Sciences, 2014, 1327, 27-45.	3.8	35
57	A silent agonist of Î±7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE. Brain, Behavior, and Immunity, 2020, 87, 286-300.	4.1	35
58	Use of an Î±3Î²4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties. Neuropharmacology, 2012, 63, 538-546.	4.1	33
59	Effects at a distance in Î±7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy. Neuropharmacology, 2004, 46, 1023-1038.	4.1	32
60	Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction. CNS and Neurological Disorders - Drug Targets, 2008, 7, 422-441.	1.4	32
61	Reversal of Agonist Selectivity by Mutations of Conserved Amino Acids in the Binding Site of Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2007, 282, 5899-5909.	3.4	31
62	Dissection of N,N-diethyl-Nâ€²-phenylpiperazines as Î±7 nicotinic receptor silent agonists. Bioorganic and Medicinal Chemistry, 2016, 24, 286-293.	3.0	31
63	Persistent activation of Î±7 nicotinic ACh receptors associated with stable induction of different desensitized states. British Journal of Pharmacology, 2018, 175, 1838-1854.	5.4	31
64	The Effects of Subunit Composition on the Inhibition of Nicotinic Receptors by the Amphipathic Blocker 2,2,6,6-Tetramethylpiperidin-4-yl Heptanoate. Molecular Pharmacology, 2005, 67, 1977-1990.	2.3	30
65	High Throughput Electrophysiology with Xenopus Oocytes. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 38-50.	1.1	30
66	Role of the Î±7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 90-99.	1.1	30
67	Modeling Binding Modes of Î±7 Nicotinic Acetylcholine Receptor with Ligands: The Roles of Gln117 and Other Residues of the Receptor in Agonist Binding. Journal of Medicinal Chemistry, 2008, 51, 6293-6302.	6.4	29
68	The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors. Psychopharmacology, 2014, 231, 4681-4693.	3.1	28
69	An Î±7 Nicotinic Acetylcholine Receptor Gain-of-Function Mutant That Retains Pharmacological Fidelity. Molecular Pharmacology, 2005, 68, 1863-1876.	2.3	27
70	Cysteine accessibility analysis of the human alpha7 nicotinic acetylcholine receptor ligand-binding domain identifies L119 as a gatekeeper. Neuropharmacology, 2011, 60, 159-171.	4.1	26
71	Multiple Modes of Î±7 nAChR Noncompetitive Antagonism of Control Agonist-Evoked and Allosterically Enhanced Currents. Molecular Pharmacology, 2013, 84, 459-475.	2.3	26
72	Discovery and optimization of Lu AF58801, a novel, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors: Attenuation of subchronic phencyclidine (PCP)-induced cognitive deficits in rats following oral administration. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 288-293.	2.2	26

#	Article	IF	Citations
73	A Single Point Mutation Confers Properties of the Muscle-Type Nicotinic Acetylcholine Receptor to Homomeric Î±7 Receptors. Molecular Pharmacology, 2004, 66, 169-177.	2.3	25
74	Medial septal/diagonal band cells express multiple functional nicotinic receptor subtypes that are correlated with firing frequency. Neuroscience Letters, 2005, 389, 163-168.	2.1	25
75	Discovery of novel Î±7 nicotinic receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4825-4830.	2.2	25
76	Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds. Nicotine and Tobacco Research, 2019, 21, 805-812.	2.6	25
77	Muscle-type nicotinic acetylcholine receptor delta subunit determines sensitivity to noncompetitive inhibitors, while gamma subunit regulates divalent permeability. Neuropharmacology, 1996, 35, 1547-1556.	4.1	24
78	Differential Regulation of Receptor Activation and Agonist Selectivity by Highly Conserved Tryptophans in the Nicotinic Acetylcholine Receptor Binding Site. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 40-53.	2.5	24
79	Positive modulation of Î±7 nAChR responses in rat hippocampal interneurons to full agonists and the Î±7-selective partial agonists, 4OH-GTS-21 and S 24795. Neuropharmacology, 2009, 56, 821-830.	4.1	24
80	Tricks of Perspective: Insights and Limitations to the Study of Macroscopic Currents for the Analysis of nAChR Activation and Desensitization. Journal of Molecular Neuroscience, 2010, 40, 77-86.	2.3	24
81	Allosteric Agonism of Î±7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. Molecular Pharmacology, 2019, 95, 606-614.	2.3	24
82	Tethered Agonist Analogs as Site-Specific Probes for Domains of the Human Î±7 Nicotinic Acetylcholine Receptor that Differentially Regulate Activation and Desensitization. Molecular Pharmacology, 2010, 78, 1012-1025.	2.3	23
83	Similar activity of mecamylamine stereoisomers in vitro and in vivo. European Journal of Pharmacology, 2013, 720, 264-275.	3.5	23
84	The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Î± represents a new antinociceptive signaling pathway in mice. Experimental Neurology, 2017, 295, 194-201.	4.1	23
85	The Î±7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology, 2019, 320, 113010.	4.1	23
86	The Î±7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal <i>Il²B</i> and <i>CD11b</i> gene expression in mice. Drug Discoveries and Therapeutics, 2017, 11, 206-211.	1.5	22
87	Selective Inhibition of Acetylcholine-Evoked Responses of Î±7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists. Molecular Pharmacology, 2009, 76, 652-666.	2.3	21
88	Macroscopic and Microscopic Activation of Î±7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Molecular Pharmacology, 2019, 95, 43-61.	2.3	21
89	Differential Modulation of Brain Nicotinic Acetylcholine Receptor Function by Cytisine, Varenicline, and Two Novel Bispidine Compounds: Emergent Properties of a Hybrid Molecule. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 424-437.	2.5	20
90	Sensitivity to Voltage-Independent Inhibition Determined by Pore-Lining Region of the Acetylcholine Receptor. Biophysical Journal, 1998, 74, 2306-2317.	0.5	19

#	Article	IF	Citations
91	2-(2-Piperidyl)- and 2-(2-Pyrrolidyl)chromans as Nicotine Agonists:Â Synthesis and Preliminary Pharmacological Characterization. Journal of Medicinal Chemistry, 2001, 44, 4704-4715.	6.4	19
92	Septal innervation regulates the function of Î±7 nicotinic receptors in CA1 hippocampal interneurons. Experimental Neurology, 2005, 195, 342-352.	4.1	19
93	Inhibition of Wild-Type and Mutant Neuronal Nicotinic Acetylcholine Receptors by Local Anesthetics. Molecular Pharmacology, 2001, 60, 1365-1374.	2.3	17
94	The Antinociceptive and Anti-Inflammatory Properties of the Î±7 nAChR Weak Partial Agonist p-CF₃N,N-diethyl-Nâ€²-phenylpiperazine. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 203-214.	2.5	17
95	Rhesus monkey Î±7 nicotinic acetylcholine receptors: Comparisons to human Î±7 receptors expressed in Xenopus oocytes. European Journal of Pharmacology, 2005, 524, 11-18.	3.5	16
96	Quinuclidines as selective agonists for alpha-7 nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1520-1522.	2.2	16
97	The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. Bioorganic and Medicinal Chemistry, 2013, 21, 7309-7329.	3.0	16
98	Identification of Î±7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidineâ€”²â€isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation. ChemMedChem, 2017, 12, 1335-1348.	3.2	15
99	Pharmacological modulation of the Î±7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal. Psychopharmacology, 2018, 235, 1897-1905.	3.1	15
100	The Î±7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-Î± in the hippocampus in mice. Pharmacological Reports, 2019, 71, 1168-1176.	3.3	15
101	Betel Nut (areca) and Smokeless Tobacco Use in Myanmar. Substance Use and Misuse, 2020, 55, 1385-1394.	1.4	15
102	Cholinergic Receptors and Addiction. Current Topics in Behavioral Neurosciences, 2020, 45, 123-151.	1.7	15
103	In vivo characterization of a novel inhibitor of CNS nicotinic receptors. European Journal of Pharmacology, 2005, 521, 43-48.	3.5	14
104	The characterization of a novel rigid nicotine analog with Î±7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3874-3880.	2.2	14
105	Perspectives on areca nut with some global implications: Symposium report. Translational Research in Oral Oncology, 2018, 3, 2057178X1881406.	3.3	14
106	B-973, a Novel Î±7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation. ACS Medicinal Chemistry Letters, 2018, 9, 1144-1148.	2.8	14
107	The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: The influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. Bioorganic and Medicinal Chemistry, 2013, 21, 7283-7308.	3.0	12
108	Synthesis, Pharmacological Characterization, and Structureâ€“Activity Relationships of Noncanonical Selective Agonists for Î±7 nAChRs. Journal of Medicinal Chemistry, 2019, 62, 10376-10390.	6.4	12

#	Article	IF	Citations
109	Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation. European Journal of Medicinal Chemistry, 2020, 205, 112669.	5.5	12
110	Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of Î±7 nAChR. Molecular Pharmacology, 2020, 98, 292-302.	2.3	12
111	Enhanced Inhibition of a Mutant Neuronal Nicotinic Acetylcholine Receptor by Agonists: Protection of Function by (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine (TC-2403). Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 765-773.	2.5	11
112	NS6740, an Î±7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity. Neuroscience Letters, 2018, 677, 6-13.	2.1	11
113	Comparison of the Anti-inflammatory Properties of Two Nicotinic Acetylcholine Receptor Ligands, Phosphocholine and pCF3-diEPP. Frontiers in Cellular Neuroscience, 2022, 16, 779081.	3.7	11
114	Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology, 2007, 74, 1271-1282.	4.4	10
115	Sulfonium as a Surrogate for Ammonium: A New Î±7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity. Journal of Medicinal Chemistry, 2017, 60, 7928-7934.	6.4	10
116	Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant Î² Subunits Acquire Sensitivity to Î±7-Selective Positive Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 252-268.	2.5	10
117	Allosterically Potentiated Î±7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium. Molecular Pharmacology, 2020, 98, 695-709.	2.3	10
118	Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives. Molecular Pharmacology, 2020, 98, 328-342.	2.3	10
119	Selective Agonists and Antagonists of Î±9 Versus Î±7 Nicotinic Acetylcholine Receptors. ACS Chemical Neuroscience, 2022, 13, 624-637.	3.5	10
120	Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the Î±7 nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation. European Journal of Medicinal Chemistry, 2018, 160, 207-228.	5.5	9
121	Potential State-selective Hydrogen Bond Formation Can Modulate Activation and Desensitization of the Î±7 Nicotinic Acetylcholine Receptor. Journal of Biological Chemistry, 2012, 287, 21957-21969.	3.4	8
122	Betel Quid, Health, and Addiction. Substance Use and Misuse, 2020, 55, 1528-1532.	1.4	8
123	In Silico Modeling of the Î±7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling. Mini-Reviews in Medicinal Chemistry, 2020, 20, 841-864.	2.4	7
124	Effects of Î±7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator on BDNF, NKCC1 and KCC2 Expression in the Hippocampus following Lipopolysaccharide-induced Allodynia and Hyperalgesia in a Mouse Model of Inflammatory Pain. CNS and Neurological Disorders - Drug Targets, 2020, 19, 366-377.	1.4	7
125	The Allosteric Activation of Î±7 nAChR by Î±-Conotoxin MrIC Is Modified by Mutations at the Vestibular Site. Toxins, 2021, 13, 555.	3.4	5
126	Coffee and cigarettes: Modulation of high and low sensitivity Î±4Î²2 nicotinic acetylcholine receptors by n-MP, a biomarker of coffee consumption. Neuropharmacology, 2022, 216, 109173.	4.1	5

#	Article	IF	Citations
127	Modulation of spontaneous hippocampal synaptic events with 5-hydroxyindole, 4OH-GTS-21, and rAAV-mediated Î±7 nicotinic receptor gene transfer. Brain Research, 2008, 1203, 51-60.	2.2	4
128	Synthesis of H-bonding probes of Î±7 nAChR agonist selectivity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 474-476.	2.2	4
129	Stable desensitization of Î±7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. European Journal of Pharmacology, 2021, 905, 174179.	3.5	4
130	Point-to-point ligandâ€“receptor interactions across the subunit interface modulate the induction and stabilization of conformational states of alpha7 nAChR by benzylidene anabaseines. Biochemical Pharmacology, 2013, 85, 817-828.	4.4	3
131	Design, synthesis, and biological activity of 5â€²-phenyl-1,2,5,6-tetrahydro-3,3â€²-bipyridine analogues as potential antagonists of nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4350-4353.	2.2	2
132	Sulfonium Ligands of the Î±7 nAChR. Molecules, 2021, 26, 5643.	3.8	2
133	Î±4Î²2 Nicotinic acetylcholine receptors, willing if able. British Journal of Pharmacology, 2010, 160, 1903-1905.	5.4	1
134	Nicotine: Understanding the big picture while also studying the details. Neuropharmacology, 2021, 196, 108715.	4.1	0
135	Nicotinic acetylcholine receptor silent agonists modulate inflammation. FASEB Journal, 2019, 33, lb236.	0.5	0